Refine
Has Fulltext
- yes (84)
Is part of the Bibliography
- yes (84)
Year of publication
Document Type
- Journal article (83)
- Doctoral Thesis (1)
Keywords
- cancer (5)
- colorectal cancer (5)
- NRF2 (3)
- metastasis (3)
- multiple myeloma (3)
- therapy (3)
- tumor microenvironment (3)
- ATF4 (2)
- CRC (2)
- Germany (2)
- HNSCC (2)
- NSCLC (2)
- SUV (2)
- angiogenesis (2)
- apoptosis (2)
- autophagy (2)
- carcinomas (2)
- chromatin (2)
- eHealth (2)
- fatigue (2)
- head and neck cancer (2)
- immune response (2)
- machine learning (2)
- melanoma (2)
- metabolomics (2)
- mind–body intervention (2)
- outcome (2)
- p53 (2)
- pediatric adrenocortical cancer (2)
- pediatric adrenocortical tumor (2)
- psycho-oncology (2)
- psychoeducation (2)
- radiotherapy (2)
- treatment (2)
- 3D lung tumor tissue models (1)
- ALT (1)
- AMPK (1)
- ATG7 (1)
- ATM (1)
- ATRX (1)
- Akt (1)
- Alzheimer’s dementia (1)
- B-cell lymphoma (1)
- BM (1)
- Bruton's tyrosine kinase inhibitor CC-292 (1)
- CA19-9 (1)
- CD30 (1)
- CD44 (1)
- CHAC1 (1)
- CMR (1)
- COVID-19 (1)
- COVID-19 pandemic (1)
- CX5461 (1)
- CYP24A1 (1)
- CYP2W1 (1)
- Carfilzomib (1)
- Chains (1)
- Clonality (1)
- Compound 3k (1)
- Cushing (1)
- Cushing syndrome (1)
- Cushing’s syndrome (1)
- DASA-58 (1)
- DCM genetic background (1)
- DNA repair protraction (1)
- DNA-PK (1)
- DUB inhibitor (1)
- Delta Repertoire (1)
- Design (1)
- EGF (1)
- EGFR (1)
- EMT (1)
- EZH2 (1)
- Epitope (1)
- FBXW7 (1)
- FGF-pathway (1)
- FGFR (1)
- FGFR-inhibitors (1)
- FasL (1)
- Foxp3 (1)
- Frequency (1)
- GPCRs (1)
- GSH (1)
- Galectin-1 (1)
- HNSC (1)
- HSC (1)
- Hans algorithm (1)
- IR (1)
- Improved survival (1)
- Intestinal Intraepithelial Lymphocy (1)
- KEAP1 (1)
- KRAS biomarker signatures (1)
- LAMN (1)
- Lymph2Cx assay (1)
- Lymphoma (1)
- MAPK signaling cascades (1)
- MAX (1)
- MITF-low (1)
- MIZ1 (1)
- MTB (1)
- MTL30 (1)
- MYC (1)
- MYCN (1)
- Myelom (1)
- NFATc1 (1)
- NFE2L2 (1)
- NFκB (1)
- NOP10 (1)
- NVP-BEZ235 (1)
- Nfatc1 (1)
- Novel PI3K (1)
- PCa (1)
- PET (1)
- PET/CT (1)
- PI3K (1)
- PKM2 (1)
- PPGL (1)
- PSMA (1)
- PSMA-TV (1)
- PTEN (1)
- Plasmozytom (1)
- Proteasominhibitor (1)
- RBM20 mutations (1)
- RCC (1)
- RNAPOL1 (1)
- Rectal cancer (1)
- Rituximab (1)
- SARS-CoV-2 (1)
- SCC (1)
- SLC7A11 (1)
- SSI (1)
- Solid tumors (1)
- Sprue (1)
- T-cells (1)
- TERT (1)
- TGF-alpha (1)
- TKI (1)
- TME (1)
- TNFα (1)
- TPCA1 (1)
- TXNIP (1)
- Tp63 (1)
- Tregs (regulatory T cells) (1)
- UMAP (1)
- USP25 (1)
- USP28 (1)
- Usage (1)
- VDR (1)
- Warburg effect (1)
- Wilms tumor (1)
- YAP5SA (1)
- Yoga (1)
- ZfKD (1)
- acute appendicitis (1)
- acute myeloid leukaemia (1)
- acute myeloid leukemia (1)
- adjuvant treatment (1)
- adrenal glands (1)
- adrenal surgery (1)
- adrenal tumours (1)
- adrenalectomia (1)
- adrenocortical adenocarcinoma (1)
- adrenocortical cancer (1)
- adrenocortical carcinoma (1)
- adrenocortical carcinoma (ACC) (1)
- adrenocortical development (1)
- adrenocortical tumors (1)
- age (1)
- anastomosis (1)
- angiogenesis inhibitors (1)
- antibiotics (1)
- antiphospholipid syndrome (1)
- anxiety (1)
- aplastic anemia (1)
- appendectomy (1)
- appendicitis (1)
- appendix (1)
- autoantibodies (1)
- bacterial infections (1)
- biased signaling (1)
- biomarker (1)
- biomarkers (1)
- blood pressure (1)
- bone adaptation (1)
- bone marrow failure (1)
- bone marrow immune-microenvironment (1)
- bone metastasis (1)
- boolean in silico models (1)
- brain metastases (1)
- c-MYC (1)
- caco-2 cells (1)
- cancer care (1)
- cancer diagnosis (1)
- cancer metabolism (1)
- cancer predisposition syndromes (1)
- cancer treatment (1)
- cancer-induced bone disease (1)
- cancer-testis antigens (1)
- cardiac thrombi (1)
- cell biology (1)
- cell cycle (1)
- cell migration (1)
- cell of origin (1)
- cerebral metastases (1)
- cholestasis (1)
- clinical malformations (1)
- clinical trials (1)
- cognitive impairment (1)
- colon (1)
- colon resection (1)
- complementary alternative medicine (1)
- complementary medicine (1)
- complication (1)
- confounders (1)
- conventional laparoscopic appendectomy (1)
- cost-effectiveness (1)
- cutaneous T-cell-lymphoma (1)
- cytopenia (1)
- depression (1)
- developmental biology (1)
- diffuse large B-cell lymphoma (1)
- disorder of immunity (1)
- distress (1)
- donor-site morbidity (1)
- drug repurposing (1)
- drug resistance (1)
- drug therapy (1)
- eEF1A1 (1)
- ectodomain cleavage (1)
- efficacy (1)
- engaging aantibody (1)
- epidemiology (1)
- evolutionary genetics (1)
- fibroblast activation protein (1)
- fibrosis (1)
- free skin grafts (1)
- free survival (1)
- gammadelta T cells (1)
- gastrointestinal infection (1)
- gene expression (1)
- general medicine (1)
- genetic markers (1)
- genome (1)
- geriatric (1)
- glycolysis (1)
- heart (1)
- heart failure (1)
- helminthes (1)
- hematopoiesis (1)
- hematopoietic stem cells (1)
- homeostasis (1)
- hormones (1)
- hypercortisolism (1)
- hypertension (1)
- hypogammaglobulinemia (1)
- hypoxia (1)
- immune infiltration (1)
- immune-checkpoint inhibitor (1)
- immunohistochemistry techniques (1)
- immunosurveillance (1)
- immunotherapy (1)
- individual mind state (1)
- induction (1)
- inflammation (1)
- inhibitor (1)
- integrated stress response (1)
- interactome (1)
- invasion (1)
- isturisa (1)
- kidney cancer (1)
- laparoscopic appendectomy (1)
- large cell transformation (1)
- left hemicolectomy (1)
- lifestyle habits (1)
- lineage (1)
- lineage differentiation (1)
- long-term effects (1)
- low-grade mucinous neoplasm (1)
- lymphocytes (1)
- lymphoma (1)
- mRNA (1)
- mTOR Inhibitor (1)
- mass spectrometry (1)
- matrix metalloproteinase (1)
- mechanical loading (1)
- medical therapy (1)
- meta-analysis (1)
- methylation (1)
- metyrapone (1)
- miR (1)
- miRNA (1)
- mind-body-intervention (1)
- mitotane (1)
- molecular alterations (1)
- molecular imaging (1)
- molecular subtypes (1)
- monogenetic cardiomyopathies (1)
- morphological features (1)
- mortality (1)
- motivational level (1)
- multicenter (1)
- mutation screening (1)
- mutation triggers (1)
- mycosis fungoides (1)
- myocardial infarction (1)
- negative pressure wound therapy (1)
- nephroblastoma (1)
- nephroblastomatosis (1)
- network pharmacology (1)
- neuroblastoma (1)
- neuroblastoma – diagnosis (1)
- neurofilament light chain (1)
- octogenarians (1)
- octogenerians (1)
- older adult (1)
- oncogenic YAP (1)
- oncology (1)
- open appendectomy (1)
- open wound treatment (1)
- operative (1)
- oral potentially malignant disorders (1)
- osilodrostat (1)
- outcomes research (1)
- outreach (1)
- pancreatic adenocarcinoma (PDAC) (1)
- pancreatic cancer (1)
- panel sequencing (1)
- paraganglioma (1)
- parathyroid hormone 1 receptor (1)
- patient access (1)
- pediatric (1)
- pediatric adrenocortical adenoma (1)
- pediatric adrenocortical carcinoma (1)
- pheochromocytoma (1)
- pheochromocytoma/paraganglioma (1)
- phosphorylated tau protein (1)
- phosphorylation (1)
- plasma NMR (1)
- platelet-rich fibrin (1)
- postoperative inflammation (1)
- preanalytical conditions (1)
- precision medicine (1)
- precision oncology (1)
- predictive factors (1)
- primary aldosteronism (1)
- primary cutaneous follicular B-cell lymphoma (1)
- prognostic biomarker (1)
- prognostic factors (1)
- prognostic-biomarkers (1)
- prospective studies (1)
- prostate adenocarcinoma (1)
- prostate cancer (1)
- protein expression (1)
- protein synthesis (1)
- protozoa infections (1)
- radial forearm flap (1)
- radiation response (1)
- radioligand therapy (1)
- radiosensibility (1)
- radiotherapy (RT) (1)
- real world data (1)
- recurrence (1)
- recurrence free survival (1)
- reminder e-mails (1)
- renal cell carcinoma (1)
- renal function (1)
- ribosome (1)
- risk factors and etiology (1)
- risk stratification (1)
- robotic surgery (1)
- secondary skin closure (1)
- single-port appendectomy (1)
- skeletal mechanobiology (1)
- small interferring RNA (1)
- squamous (1)
- stem-cell transplantation (1)
- stemness (1)
- stress (1)
- supportive care intervention (1)
- surgery (1)
- surgical (1)
- surgical oncology (1)
- surgical procedures (1)
- surgical site infection (1)
- surgical site infections (1)
- symptom burden (1)
- systematic review (1)
- t-SNE (1)
- targeted combination therapy (1)
- targeted sequencing (1)
- taxane (1)
- telomeres (1)
- thiol starvation (1)
- timing (1)
- transcription (1)
- transcriptome (1)
- transcriptomic analysis (1)
- transcriptomics (1)
- translation initiation (1)
- tumor surveillance (1)
- tyrosine kinase inhibitors (1)
- venous infiltration (1)
- visual clustering (1)
- vitamin D (1)
- vitamin D receptor (1)
- volume (1)
- wound infection (1)
- ΔNp63 (1)
Institute
- Comprehensive Cancer Center Mainfranken (84) (remove)
Schriftenreihe
Sonstige beteiligte Institutionen
- Zentraleinheit Klinische Massenspektrometrie (2)
- IZKF Nachwuchsgruppe Geweberegeneration für muskuloskelettale Erkrankungen (1)
- Interdisciplinary Center for Clinical Research (1)
- Lehrstuhl für Regeneration Muskuloskelettaler Gewebe (1)
- Mildred Scheel Early Career Center (1)
- Muskuloskelettales Centrum Würzburg (MCW) (1)
EU-Project number / Contract (GA) number
- 633983 (2)
- 232944 (1)
- BWF/H/52228/2012/13.10.10-1/3.4,6 (1)
The cystine/glutamate antiporter xCT is an important source of cysteine for cancer cells. Once taken up, cystine is reduced to cysteine and serves as a building block for the synthesis of glutathione, which efficiently protects cells from oxidative damage and prevents ferroptosis. As melanomas are particularly exposed to several sources of oxidative stress, we investigated the biological role of cysteine and glutathione supply by xCT in melanoma. xCT activity was abolished by genetic depletion in the Tyr::CreER; Braf\(^{CA}\); Pten\(^{lox/+}\) melanoma model and by acute cystine withdrawal in melanoma cell lines. Both interventions profoundly impacted melanoma glutathione levels, but they were surprisingly well tolerated by murine melanomas in vivo and by most human melanoma cell lines in vitro. RNA sequencing of human melanoma cells revealed a strong adaptive upregulation of NRF2 and ATF4 pathways, which orchestrated the compensatory upregulation of genes involved in antioxidant defence and de novo cysteine biosynthesis. In addition, the joint activation of ATF4 and NRF2 triggered a phenotypic switch characterized by a reduction of differentiation genes and induction of pro-invasive features, which was also observed after erastin treatment or the inhibition of glutathione synthesis. NRF2 alone was capable of inducing the phenotypic switch in a transient manner. Together, our data show that cystine or glutathione levels regulate the phenotypic plasticity of melanoma cells by elevating ATF4 and NRF2.
RBM20 mutations account for 3 % of genetic cardiomypathies and manifest with high penetrance and arrhythmogenic effects. Numerous mutations in the conserved RS domain have been described as causing dilated cardiomyopathy (DCM), whereas a particular mutation (p.R634L) drives development of a different cardiac phenotype: left-ventricular non-compaction cardiomyopathy. We generated a mutation-induced pluripotent stem cell (iPSC) line in which the RBM20-LVNC mutation p.R634L was introduced into a DCM patient line with rescued RBM20-p.R634W mutation. These DCM-634L-iPSC can be differentiated into functional cardiomyocytes to test whether this RBM20 mutation induces development of the LVNC phenotype within the genetic context of a DCM patient.
At the beginning of the COVID-19 pandemic, patients with primary and secondary immune disorders — including patients suffering from cancer — were generally regarded as a high-risk population in terms of COVID-19 disease severity and mortality. By now, scientific evidence indicates that there is substantial heterogeneity regarding the vulnerability towards COVID-19 in patients with immune disorders. In this review, we aimed to summarize the current knowledge about the effect of coexistent immune disorders on COVID-19 disease severity and vaccination response. In this context, we also regarded cancer as a secondary immune disorder. While patients with hematological malignancies displayed lower seroconversion rates after vaccination in some studies, a majority of cancer patients’ risk factors for severe COVID-19 disease were either inherent (such as metastatic or progressive disease) or comparable to the general population (age, male gender and comorbidities such as kidney or liver disease). A deeper understanding is needed to better define patient subgroups at a higher risk for severe COVID-19 disease courses. At the same time, immune disorders as functional disease models offer further insights into the role of specific immune cells and cytokines when orchestrating the immune response towards SARS-CoV-2 infection. Longitudinal serological studies are urgently needed to determine the extent and the duration of SARS-CoV-2 immunity in the general population, as well as immune-compromised and oncological patients.
(1) Background: Clear cell renal cell carcinoma extending into the inferior vena cava (ccRCC\(^{IVC}\)) represents a clinical high-risk setting. However, there is substantial heterogeneity within this patient subgroup regarding survival outcomes. Previously, members of our group developed a microRNA(miR)-based risk classifier — containing miR-21-5p, miR-126-3p and miR-221-3p expression — which significantly predicted the cancer-specific survival (CSS) of ccRCC\(^{IVC}\) patients. (2) Methods: Examining a single-center cohort of tumor tissue from n = 56 patients with ccRCC\(^{IVC}\), we measured the expression levels of miR-21, miR-126, and miR-221 using qRT-PCR. The prognostic impact of clinicopathological parameters and miR expression were investigated via single-variable and multivariable Cox regression. Referring to the previously established risk classifier, we performed Kaplan–Meier analyses for single miR expression levels and the combined risk classifier. Cut-off values and weights within the risk classifier were taken from the previous study. (3) Results: miR-21 and miR-126 expression were significantly associated with lymphonodal status at the time of surgery, the development of metastasis during follow-up, and cancer-related death. In Kaplan–Meier analyses, miR-21 and miR-126 significantly impacted CSS in our cohort. Moreover, applying the miR-based risk classifier significantly stratified ccRCC\(^{IVC}\) according to CSS. (4) Conclusions: In our retrospective analysis, we successfully validated the miR-based risk classifier within an independent ccRCC\(^{IVC}\) cohort.
Background
International guidelines emphasise the role of radiotherapy (RT) for the management of advanced adrenocortical carcinoma (ACC). However, the evidence for this recommendation is very low.
Methods
We retrospectively analysed all patients who received RT for advanced ACC in five European centres since 2000. Primary endpoint: time to progression of the treated lesion (tTTP). Secondary endpoints: best objective response, progression-free survival (PFS), overall survival (OS), adverse events, and the establishment of predictive factors by Cox analyses.
Results
In total, 132 tumoural lesions of 80 patients were treated with conventional RT (cRT) of 50–60 Gy (n = 20) or 20–49 Gy (n = 69), stereotactic body RT of 35–50 Gy (SBRT) (n = 36), or brachytherapy of 12–25 Gy (BT) (n = 7). Best objective lesional response was complete (n = 6), partial (n = 52), stable disease (n = 60), progressive disease (n = 14). Median tTTP was 7.6 months (1.0–148.6). In comparison to cRT\(_{20-49Gy}\), tTTP was significantly longer for cRT\(_{50-60Gy}\) (multivariate adjusted HR 0.10; 95% CI 0.03–0.33; p < 0.001) and SBRT (HR 0.31; 95% CI 0.12–0.80; p = 0.016), but not for BT (HR 0.66; 95% CI 0.22–1.99; p = 0.46). Toxicity was generally mild and moderate with three grade 3 events. No convincing predictive factors could be established.
Conclusions
This largest published study on RT in advanced ACC provides clear evidence that RT is effective in ACC.
(1) Background: C-X-C Motif Chemokine Receptor 4 (CXCR4) and Fibroblast Activation Protein Alpha (FAP) are promising theranostic targets. However, it is unclear whether CXCR4 and FAP positivity mark distinct microenvironments, especially in solid tumors. (2) Methods: Using Random Forest (RF) analysis, we searched for entity-independent mRNA and microRNA signatures related to CXCR4 and FAP overexpression in our pan-cancer cohort from The Cancer Genome Atlas (TCGA) database — representing n = 9242 specimens from 29 tumor entities. CXCR4- and FAP-positive samples were assessed via StringDB cluster analysis, EnrichR, Metascape, and Gene Set Enrichment Analysis (GSEA). Findings were validated via correlation analyses in n = 1541 tumor samples. TIMER2.0 analyzed the association of CXCR4 / FAP expression and infiltration levels of immune-related cells. (3) Results: We identified entity-independent CXCR4 and FAP gene signatures representative for the majority of solid cancers. While CXCR4 positivity marked an immune-related microenvironment, FAP overexpression highlighted an angiogenesis-associated niche. TIMER2.0 analysis confirmed characteristic infiltration levels of CD8+ cells for CXCR4-positive tumors and endothelial cells for FAP-positive tumors. (4) Conclusions: CXCR4- and FAP-directed PET imaging could provide a non-invasive decision aid for entity-agnostic treatment of microenvironment in solid malignancies. Moreover, this machine learning workflow can easily be transferred towards other theranostic targets.
Butyrophilin (BTN)–3A and BTN2A1 molecules control the activation of human Vγ9Vδ2 T cells during T cell receptor (TCR)-mediated sensing of phosphoantigens (PAg) derived from microbes and tumors. However, the molecular rules governing PAg sensing remain largely unknown. Here, we establish three mechanistic principles of PAg-mediated γδ T cell activation. First, in humans, following PAg binding to the intracellular BTN3A1-B30.2 domain, Vγ9Vδ2 TCR triggering involves the extracellular V-domain of BTN3A2/BTN3A3. Moreover, the localization of both protein domains on different chains of the BTN3A homo-or heteromers is essential for efficient PAg-mediated activation. Second, the formation of BTN3A homo-or heteromers, which differ in intracellular trafficking and conformation, is controlled by molecular interactions between the juxtamembrane regions of the BTN3A chains. Finally, the ability of PAg not simply to bind BTN3A-B30.2, but to promote its subsequent interaction with the BTN2A1-B30.2 domain, is essential for T-cell activation. Defining these determinants of cooperation and the division of labor in BTN proteins improves our understanding of PAg sensing and elucidates a mode of action that may apply to other BTN family members.
Introduction: National and international guidelines recommend early integration of evidence-based multimodal interventions and programs, especially with a focus on relaxation techniques and other Mind–Body-based methods to maintain the quality of life of oncology patients, improve treatment tolerability, and promote healthy lifestyle behaviors. Consequently, we aim to understand what drives patients and how they navigate integrative medicine to best advise them. This study aimed to detect possible topics of particular interest to patients and identify the patient groups that could benefit most from further programs. Furthermore, we aimed to investigate if patients are open-minded toward integrative oncology concepts and learn about their motivational level to maintain or change behavior.
Methods: Between August 2019 and October 2020 we surveyed patients undergoing oncological therapy in a university oncological outpatient center using a custom-developed questionnaire based on established Mind–Body Medicine concepts.
Results: We included 294 patients with various cancers. More than half reported problems sleeping through (61%) and 42% felt stressed frequently, invariably rating this as detrimental to their health. Moreover, a slight majority (52%) felt physically limited due to their disease and only 30% performed defined exercise programs. Women were significantly more likely to feel stressed and reported with alarming frequency that they often feel “everything was up to them.” The 40–65-year-olds reported significantly less restful sleep, more stress and were more dissatisfied with their situation. However, this group already used natural remedies most frequently and was most often motivated to use relaxation techniques in the next 6 months. The lower the perceived individual energy level (EL), the less frequently patients did sport, the more frequently they felt their disease impaired their activity, mostly feeling stressed and tense. We also found significant associations between negative emotions/thoughts and the variables “sleep,” “use of relaxation techniques,” “personal stress perception,” and “successful lifestyle modification.”
Conclusion: Mind–Body programs that focus on patient’s individual resources, with tools to explore impairing patterns of self-perception and cognitive biases, can be a valuable resource for oncology patients and should therefore be part of an integrative medical treatment concept.
Highlights
• The integrated stress response leads to a general ATF4-dependent activation of NRF2
• ATF4 causes a CHAC1-dependent GSH depletion, resulting in NRF2 stabilization
• An elevation of NRF2 transcript levels fosters this effect
• NRF2 supports the ISR/ATF4 pathway by improving cystine and antioxidant supply
Summary
The redox regulator NRF2 becomes activated upon oxidative and electrophilic stress and orchestrates a response program associated with redox regulation, metabolism, tumor therapy resistance, and immune suppression. Here, we describe an unrecognized link between the integrated stress response (ISR) and NRF2 mediated by the ISR effector ATF4. The ISR is commonly activated after starvation or ER stress and plays a central role in tissue homeostasis and cancer plasticity. ATF4 increases NRF2 transcription and induces the glutathione-degrading enzyme CHAC1, which we now show to be critically important for maintaining NRF2 activation. In-depth analyses reveal that NRF2 supports ATF4-induced cells by increasing cystine uptake via the glutamate-cystine antiporter xCT. In addition, NRF2 upregulates genes mediating thioredoxin usage and regeneration, thus balancing the glutathione decrease. In conclusion, we demonstrate that the NRF2 response serves as second layer of the ISR, an observation highly relevant for the understanding of cellular resilience in health and disease.